avVaa World Health Care Products Signs New Spokesman
13th Nov 2006, 16:15 GMT
avVaa World Health Care Products, a global biotech company offering therapeutic, natural skin and health care products, has signed a spokesman agreement with Doug Mills of Training Thru Trust,.
avVaa World Health Care Products Signs New Spokesman related news:
- Global Patient Safety Challenge: Clean Care is Safer Care — News-Medical News Feed
- RAND study shows little public money spent on health care to undocumented immigrants — EurekAlert! - Breaking News
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud — StratWire - Business of Healthcare NewsFeed
- Uganda: Palliative Care Has Improved - Otaala — AllAfrica News: HIV-Aids and STDs
- Little public money actually spent on health care to undocumented immigrants — Science Blog - Think. It's not illegal yet.
- AIAG Conference Explores Applying Automotive Quality Methodologies to Reduce Medical Errors, Improve Health Care Delivery and Reduce Costs — Pharmaceuticals News from StratCenter.com
- Crowd protests health care in China. — Environmental Health News
- SW Doctors PA Launch Affordable Primary Care (APC) Services — RedOrbit News - Health
- Friends, foes of D.C.'s $245M health care plan take last chance to sound off — Latest news from Washington Business Journal
- Health Integrated to Speak at World Research Group Summit on Disease Mgmt for Depression — Insurance/ Managed Care News from StratCenter.com
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout